Under the Progressive Recruitors Act of 1995, no cersons are REQUEST FOR A SESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a) In re Application, of Abdication Number Examiner Grow At Unit Paper No. Assistant Commissioner for Patents Washington, DC 20231 I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-Identified ABANDONED application, which is: (CHECK CNE; (A) referred to in United States Patent Number (B) referred to in an application that is open to public inspection as set forth in 37 CFR.1.11, i.e., Application No. \_\_\_\_\_\_ of \_\_\_\_\_ of paper number \_\_\_\_\_ (C) an application that claims the benefit of the filing cate of an application that is open to public inspection, i.e., Application No. \_ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public. Please direct any correspondence concerning this request to the following address: \_ OCI 22 1990 Date FOR PTO USE ONE Typed or printed name (Indiais) Unit:



# United States Patent [19]

Lobb et al.



[11] Patent Number:

5,932,214

[45] Date of Patent:

Aug. 3, 1999

# [54] TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH VLA-4 BLOCKERS

[75] Inventors: Roy R. Lobb. Westwood; Linda C.

Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: 08/950,660

[22] Filed: Oct. 15, 1997

## Related U.S. Application Data

[62ntinuation of application No. 08/456,124, May 31, 1995., abandoned, which is a continuation-in-part of application No. 08/373,857. Jan. 18, 1995., abandoned, which is a continuation-in-part of application No. 08/284,603, Aug. 11, 1994., abandoned, which is a continuation-in-part of application No. 07/835,139, filed as application No. PCT/US93/00924, Feb. 2, 1993., abandoned

[51]	Int. Cl. <sup>6</sup>	A61K 39/395; A61K 38/17
[52]	U.S. Cl	
	424/133.1; 424	1/134.1; 424/136.1; 424/141.1;
	424/143.4	; 424/153.1; 424/154.1; 514/2;
	514/8; 514/885; 5	30/350; 530/387.1; 530/387.3;
	530/388.1; 530/	388.2; 530/388.22; 530/388.7;
		530/388.73; 530/388.75
[58]	Field of Search	424/130.1, 133.1,
	424/141.1. 15	3.1; 514/2, 8; 530/350, 388.1,
		388.7

#### [56] References Cited

### U.S. PATENT DOCUMENTS

4,816,397	3/1989	Boss et al 435/68
4,833,092	5/1989	Geysen 436/501
5,116,964	5/1992	Capon et al
5,272,263	12/1993	Hession et al
5,730,978	3/1998	Wayner.

#### FOREIGN PATENT DOCUMENTS

0 314 863	5/1989	European Pat. Off.
0 330 506	9/1989	European Pat. Off.
0 333 517	9/1989	European Pat. Off.
0 346 078	12/1989	European Pat. Off.
WO 90/03400	<b>* 4/1990</b> .	WIPO.
WO 90/13300	11/1990	WIPO.
9103252	3/1991	WIPO.
WO 92/00751	1/1992	WIPO.
WO 93/13798	1/1992	WIPO.
WO 95/19790	7/1995	WIPO.

# OTHER PUBLICATIONS

Jakubowski, et al. "Vascular Cell Adhesion Molecule (VCAM)—Ig Fusion Protein Defines Distinct Affinity States of the Very Late Antigen—4 (VLA—4) Receptor" Cell Adhesion and Communication 3:131–142 (1995).

Brown, Jr., P. et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival" *Proc. Natl. Acad. Sci. USA* 88:2663-2667 (1990).

Burkly, L. et al., "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation" Eur. J. Immunol. 21:2871-2875 (1991).

Clackson, T. et al., "Making Antibody Fragments Using Phage Display Libraries" Nature 352:624-628 (1991).

Co. M.S. et al., "Humanized Antibodies for Antiviral Therapy" *Proc. Natl. Acad. Sci. USA* 88:2869–2873 (1990). Damle, N. et al., "Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4<sup>+</sup> T Lymphocytes" *Proc. Natl. Acad. Sci. USA* 88:6403–6407 (1991).

Devlin, J. et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" Science 249:400-406 (1990).

Dobrina, A. et al., "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells" J. Clin. Invest. 88:20-26 (1991).

Elices, M.J. et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site" Cell 60:577-584 (1990).

Freedman, A. et al., "Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110" Science 249:1030-1033 (1990).

Harris, W.J. and S. Emery, "Therapeutic antibodies—the coming of age" TIBTECH 11: 42-44 (1993).

Hemler, M. E. et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides" J. Biol. Chem. 262(24):11478-11485 (1987).

Holzmann, B. and I.L. Weissman, "Integrin Molecules Involved in Lymphocyte Homing to Peyer's Patches" *Immunolical Reviews* 0(108):45-61 (1989).

Podolsky, D.K. et al., "Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin" Gastroent. 88:20-25 (1985).

Podolsky, D.K. et al., "Spontaneous Colitis In Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chromic Colitis" Digestive Diseases and Sciences 30(4):396 (A-32) (1985).

Pulido, R. et al., "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4" J. Biol. Chem. 266(16):10241-10245 (1991).

Rice, G.E. et al., "Vascular and Nonvascular Expression of INCAM-110", Am. J. Pathology 138(2):385-393 (1991).

Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (1988).

### (List continued on next page.)

Primary Examiner—Christina Y. Chan
Assistant Examiner—Phillip Gambel
Attorney, Agent, or Firm—Fish & Richardson P.C.:

## [57] ABSTRACT

A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.

## 15 Claims, 8 Drawing Sheets

٠.